Chronic mucosal inflammation and tissue damage predisposes patients to the development of colorectal cancer 1 . This association could be explained by the hypothesis that the same factors and pathways important for wound healing also promote tumorigenesis. A sensor of tissue damage should induce these factors to promote tissue repair and regulate their action to prevent development of cancer. Interleukin 22 (IL-22), a cytokine of the IL-10 superfamily, has an important role in colonic epithelial cell repair, and its levels are increased in the blood and intestine of inflammatory bowel disease patients 2,3 . This cytokine can be neutralized by the soluble IL-22 receptor, known as the IL-22 binding protein (IL-22BP, also known as IL22RA2); however, the significance of endogenous IL-22BP in vivo and the pathways that regulate this receptor are unknown 4, 5 . Here we describe that IL-22BP has a crucial role in controlling tumorigenesis and epithelial cell proliferation in the colon. IL-22BP is highly expressed by dendritic cells in the colon in steady-state conditions. Sensing of intestinal tissue damage via the NLRP3 or NLRP6 inflammasomes led to an IL-18-dependent downregulation of IL-22BP, thereby increasing the ratio of IL-22/ IL-22BP. IL-22, which is induced during intestinal tissue damage, exerted protective properties during the peak of damage, but promoted tumour development if uncontrolled during the recovery phase. Thus, the IL-22-IL-22BP axis critically regulates intestinal tissue repair and tumorigenesis in the colon.
IL-22 is produced by innate lymphoid cells, T H 17 cells, and T H 22 cells, particularly at mucosal surfaces [5] [6] [7] . The membrane-bound IL-22 receptor 1 (IL-22R1, also known as IL22RA1) is absent on immune cells, but expressed within tissues, such as the epithelial cells of the gastrointestinal tract and skin 4 . IL-22 has an important function in the promotion of antimicrobial immunity via induction of antimicrobial peptides, and in tissue repair via induction of epithelial cell proliferation and survival 5, 8, 9 . However, IL-22 can also promote pathological inflammatory responses in the skin 10 or intestine 11 in mouse models, and its concentration is increased in a variety of human diseases including psoriasis, rheumatoid arthritis, infections and inflammatory bowel disease 5 . In line with the pleiotropic role(s) of IL-22, it is known that this cytokine signals via STAT3, which is important for wound healing, but also for tumour development 1 . However, the role of IL-22 during tumour development needs to be clarified, because both inhibitory and promoting effects have been reported (for review see ref. 4 ).
IL-22BP is a soluble IL-22 receptor, which lacks a transmembrane and intracellular domain. IL-22BP specifically binds to IL-22 but not to other IL-10 family members, and prevents the binding of IL-22 to membrane-bound IL-22R1 [12] [13] [14] [15] . The binding of IL-22 to IL-22BP is of 20-to 1,000-fold higher affinity compared to its binding to the membrane-bound IL-22R1 3, 16 . It is also known that IL-22BP expression is downregulated in the intestine during tissue damage. However, the cellular source of IL-22BP is unclear. Moreover, the mechanism regulating IL-22BP expression and the significance of endogenous IL-22BP in vivo are unknown 4, 5 .
IL-22BP is highly expressed in the colon ( Supplementary Fig. 1 ) and IL-22 has been suggested to have a role in tumour development. We therefore generated Il22bp 2/2 mice (Il22bp is also known as Il22ra2) ( Supplementary Fig. 2 ) and used a colitis-associated colon cancer model, which resembles the pathology of human colitis-associated neoplasia 17, 18 ( Supplementary Fig. 3 ), to analyse the role of IL-22BP during tumorigenesis in the colon. Interestingly, tumour development was strongly accelerated and the number and size of the tumours were increased in Il22bp 2/2 compared to wild-type control mice ( Fig. 1a -c). Tumour morphology was similar between Il22bp 2/2 and wild-type control mice ( Fig. 1c ). Thus, IL-22BP deficiency leads to accelerated and increased tumorigenesis in a colitis-associated colon cancer model.
Inflammation is one of the major drivers of tumour development in the colitis-associated colon cancer model 1,18 . IL-22 has been reported to have both protective and pathogenic properties during colitis 9, 11 . However, wild-type and Il22bp 2/2 mice showed no difference in colitis disease severity in the acute dextran sodium sulphate (DSS)-induced colitis model ( Supplementary Fig. 4a -g). In line with a previous report 3 , we found that Il22bp was downregulated during acute DSScolitis, and was not detectable on day 10 of the experiment (Supplementary Fig. 4g ), which could explain the lack of phenotype in Il22bp 2/2 mice. We then examined a model of chronic DSS-induced colitis in which DSS is administered for 5 days followed by 16 days of a water regimen for four separate cycles, similar to the colitis-associated colon cancer model. No difference in disease severity was observed between wild type and Il22bp 2/2 in this chronic colitis model (Supplementary Fig. 5 ).
IL-22 is well known to promote epithelial cell proliferation 4, 8 . Therefore another hypothesis for the increased experimental colon tumorigenesis in Il22bp 2/2 mice is that the effect of IL-22BP is to inhibit IL-22-induced epithelial cell proliferation. However, the significance of endogenous IL-22BP for the control of IL-22 is currently unclear 4, 5 . Furthermore, both IL-22 and IL-22BP expression are modulated during intestinal tissue damage 3, 19 . We examined the expression of IL-22 and IL-22BP during one cycle of DSS administration for 5 days followed by 16 days of water. Mice treated with DSS lost weight and developed histological signs of colitis ( Fig. 2a ). The peak of disease occurred between day 7 and day 8 ( Fig. 2a ). Il22bp messenger RNA was expressed under steady-state conditions. The lowest expression of Il22bp correlated with the peak of disease. However, Il22bp was expressed once again during the recovery phase ( Fig. 2a, b) . Consistent with previous studies 3, 9 , we found increased Il22 mRNA levels in the colon with maximal expression between day 7 and day 8 ( Fig. 2b) . Accordingly IL-22 serum levels were increased with the same pattern (data not shown). We next validated the inverse expression pattern of IL-22 and IL-22BP in another model of intestinal damage. Following wounding of the colon using an endoscopic biopsy forceps 8 (Fig. 2c ), Il22bp was expressed in the initial biopsy ( Fig. 2d ). However, 2 days later Il22bp expression was reduced in a re-biopsy close to the wound, but not in a control biopsy taken at a distance of 0.5 cm from the initial biopsy ( Fig. 2d ). Thus IL-22BP is downregulated upon damage of the epithelial barrier in the colon, but induced once again during the recovery, and IL-22 shows an inverse expression pattern to IL-22BP.
On the basis of these results we tested if IL-22BP has a significant effect on epithelial cell proliferation during DSS-induced intestinal tissue damage. There was no difference in epithelial cell proliferation between wild-type and Il22bp 2/2 mice on day 0 or 7 of the experiment. However, whereas in wild-type mice epithelial cell proliferation on day 14 was comparable to steady-state conditions, Il22bp 2/2 mice continued to demonstrate elevated epithelial cell proliferation ( Fig. 2e and Supplementary Fig. 6 ). At this time point both Il22 and Il22bp were expressed in the colon (Fig. 2b ). In line with these data, tumour cells of Il22bp 2/2 mice proliferated more compared to wild type ( Fig. 1d ). Thus endogenous IL-22BP is required to terminate the IL-22-induced regenerative program.
We generated Il22bp 2/2 Il22 2/2 double KO (dKO) mice to establish that the effect of IL-22BP is dependent on the presence of IL-22. Il22bp 2/2 Il22 2/2 mice showed a similar tumour number and score compared to Il22 2/2 mice, which was lower than the score observed in Il22bp 2/2 mice. These data confirm that the effect of IL-22BP is dependent on the presence of IL-22 ( Supplementary Fig. 7 ). Unexpectedly Il22 2/2 mice developed a higher tumour load compared to wild-type mice ( Supplementary Fig. 7) , which seems to be in contrast to the increased tumour load in Il22bp 2/2 mice. It is known, however, that Il22 2/2 mice exhibit an increased disease severity in the DSS-colitis model 9 . We therefore proposed the hypothesis that IL-22 has a dual function during colitis-associated colon cancer: Deficiency of IL-22 might lead to delayed colonic repair and increased intestinal inflammation, thereby promoting tumour development. However, the increased availability of IL-22 in Il22bp 2/2 mice during the recovery phase caused prolonged epithelial proliferation, thereby also promoting the development of intestinal tumours. In support of this hypothesis, we confirmed that Il22 2/2 mice have increased disease and inflammation with marked IL-6 production after DSS administration ( Supplementary Fig. 8 ). To further validate our hypothesis we performed two sets of experiments. First we showed, by the administration of neutralizing IL-22 antibody, that IL-22 is protective during the peak of disease, but detrimental during the recovery phase (Supplementary Fig. 9 ). Second we used a model of spontaneous tumorigenesis, in which a genetic mutation and not inflammation induces tumour development in the colon. We crossed Il22 2/2 and Il22bp 2/2 with Apc min/1 mice. Min (multiple intestinal neoplasia) mice carry a dominant mutation in the adenomatous polyposis coli (Apc) gene and develop multiple adenomas throughout their intestinal tract, mainly in the small intestine 20 . This mouse model resembles the human disease known as familial adenomatous polyposis, which is also caused by mutations in the APC gene. Humans carrying this mutation develop polyps, mainly in the colon, and malignant transformation into colon cancer occurs, if untreated, in almost 100% of the cases.
Il22bp 2/2 Apc min/1 mice developed an increased number and size of tumours, whereas Il22 2/2 Apc min/1 developed fewer tumours in the colon compared to Apc min/1 . In contrast to the human disease, in the mouse model most tumours are seen in the small intestine. The tumour number and load was also significantly lower in the small intestine of Il22 2/2 Apc min/1 compared to wild-type mice, although Il22bp 2/2 Apc min/1 showed similar tumour development in the small intestine compared to wild-type mice (Fig. 3 ). This lack of effect of the Il22bp genotype in the small intestine is in line with the expression of Il22bp, which is high in the colon and low in the small intestine ( Supplementary Fig. 1 ). Taken together, these data support our hypothesis that the increased tumour burden in Il22 2/2 mice in the colitisassociated colon cancer model is due to the increased susceptibility to DSS-induced colitis. In summary, IL-22 and IL-22BP are regulated during intestinal tissue damage. IL-22 has both protective and detrimental effects during intestinal tissue damage and therefore needs to be controlled via IL-22BP.
The cellular source of IL-22 and the mechanism regulating IL-22 expression have been studied 5, 21 . In contrast, the mechanism regulating IL-22BP expression is unknown 4, 5 . IL-22BP expression has been reported in different haematopoietic cells and also in intestinal epithelial cells 4, 14 . However, these studies contradict each other. Interestingly, we observed Il22bp expression in haematopoietic cells and preparations of epithelial cells isolated from the colon (Fig. 4a ). One caveat, however, was that the purity of the epithelial cells was about 98% and the Il22bp expression was about 50 times lower than in the haematopoietic cells. We used bone marrow chimaeras to show that the vast majority of IL-22BP expression in the colon was due to the haematopoietic compartment both in steady-state condition (Fig. 4b ) and in the colitis-associated colon cancer model ( Supplementary Fig. 10 ). We next used a stepwise approach to identify the haematopoietic source of IL-22BP in the colon. Il22bp was expressed in TCR-b 2 cells, but 
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not in TCR-b 1 cells (data not shown). Within the TCR-b 2 cells MHCII 1 CD11c 1 cells were the main source of Il22bp ( Fig. 4c and Supplementary Fig. 10 ).
Next we aimed to identify the trigger and the pathway regulating IL-22BP expression. As shown in Fig. 2 we found that Il22bp is downregulated at day two after DSS administration before the development of histological signs of disease. However, it is known that DSS induces the loss of tight junctions within 2 days, and that the epithelial barrier is therefore permeable, allowing penetrance of bacteria and bacterial products 22 . Interestingly, depletion of the bacterial flora by administration of antibiotics in the DSS-colitis model impaired the downregulation of IL-22BP (data not shown, Fig. 4e ). We therefore tested whether the downregulation of IL-22BP is dependent on MYD88 and/or TRIF signalling. To that end we used the endoscopic wounding model as described in Fig. 2 . Remarkably, Il22bp was not downregulated in Myd88 2/2 Trif 2/2 dKO mice after wounding of the colon. Moreover, expression appeared to be elevated in the wounded dKO mice compared to the unwounded tissue of these mice. As expected, Cd11c (also known as Itgax) was also upregulated in the wounded compared to the unwounded tissue. We therefore normalized Il22bp expression to Cd11c, which showed that the Il22bp expression remained stable in Myd88 2/2 Trif 2/2 dKO mice, but was drastically reduced in wild-type mice after wounding (Fig. 4d ). Finally, we could demonstrate that the downregulation of Il22bp was independent of the TLR2, TLR4, TLR5 or IL-1 pathways, but dependent on IL-18 (Fig. 4e) .
Inflammasomes are cytoplasmic multiprotein complexes that function as sensors of endogenous or exogenous stress. Inflammasomes typically assemble with the adaptor protein ASC (apoptosis-associated speck-like protein) into a multiprotein complex that leads to caspase 1 activation and subsequent cleavage of pro-IL-18 (or pro-IL-1) 23 . Accordingly, the downregulation of Il22bp was blocked in Caspase1 2/2 and Asc 2/2 mice, and we found furthermore that the NLRP3 and NLRP6 inflammasomes, but not NLRC4, were important for this process (Fig. 4e, data not shown) . Inflammasomes can be Tumour number (small intestine) Il22 2/2 mice were crossed with Apc min/1 mice. Six-months-old mice were analysed. Tumour number and size were measured using a dissecting microscope (size 1, , 2 mm; size 2, 2-5 mm; size 3, . 5 mm). Each dot represents one mouse, lines indicate mean 6 s.e.m. All mice displayed are Apc min/1 . No tumours were observed in Apc 1/1 mice regardless of the Il22 and Il22bp genotype.
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activated by host-derived factors which are released upon tissue damage, such as ATP, uric acid and hyaluronan, and also by microbial ligands 23 . Using the antibiotic treatment that we validated previously 24 , we found that the downregulation of Il22bp was partially dependent on the intestinal microbiota ( Fig. 4e) . We recently reported that Nlrp6 2/2 mice have an altered microflora 24 . We therefore co-housed wild-type mice with Nlrp6 2/2 mice, conditions under which the dysbiotic flora are transferred to co-housed recipients. But the downregulation of Il22bp upon wounding of the wild-type intestine was not impaired (fold reduction of Il22bp: wild type 0.0123 6 0.002, wild type (co-housed) 0.0118 6 0.0003, Nlrp6 2/2 (co-housed) 0.405 6 0.152). These data show that, although the downregulation of Il22bp is partially dependent on the microflora (Fig. 4e) , it is not affected by the transmissible flora of inflammasome-deficient mice. It is known that IL-18 is upregulated very early after DSS-induced intestinal tissue damage 25, 26 . We therefore tested the role of IL-18 in the modulation of IL-22BP in this model. We observed that IL-18 is crucial for the complete downregulation of Il22bp also upon DSS-induced tissue damage ( Supplementary Fig. 11 ). Whereas loss of IL-18 strongly reduced the level of downregulation of Il22bp, there was some residual downregulation of Il22bp even in the absence of IL-18, indicating that other factors may also contribute to the regulation of Il22bp.
We next aimed to further support and extent our murine in vivo data to human biology. We first validated that human dendritic cells express IL-22BP, and then we established, in vitro, that IL-18 is able to downregulate IL-22BP (also known as IL22RA2) in human ( Fig. 4f, g) and mouse dendritic cells (data not shown) in a time-and dose-dependent manner. Taken together, these data show that IL-18 downregulates Il22bp expression by CD11c 1 cells upon intestinal wounding.
Recent publications have shown that Il18 2/2 mice have increased inflammation and tumour development in the colitis-associated colon cancer model 26, 27 . This is in line with our finding that IL-18 downregulates IL-22BP, and that Il22 2/2 mice have increased inflammation and tumorigenesis in the colitis-associated colon cancer model. However, our data do not exclude other important functions of IL-18 besides the regulation of IL-22BP.
Chronic mucosal inflammation and tissue damage as seen in inflammatory bowel disease predisposes patients to the development of colorectal cancer, one of the most frequent fatal cancers in the world. This association could be explained by the hypothesis that the same factors and pathways that are important for wound healing, also promote tumorigenesis. Our data indicate that IL-22 is such a factor. Several studies have linked the microbial status with colon tumorigenesis [28] [29] [30] . These data are in line with our results that sensing of microbial ligands and intestinal tissue damage by the NLRP3 and NLRP6 inflammasomes regulates IL-22BP expression by CD11c 1 cells via caspase-1mediated IL-18 activation. This regulation of IL-22BP is crucial to control the effects of IL-22 during intestinal tissue damage and tumorigenesis ( Supplementary Fig. 12 ). Therefore we propose a link between the microflora, the epithelium and the immune system regulating the balance between tissue regeneration and tumour development in the intestine. The regulation of IL-22BP via the inflammasome provides an unanticipated mechanism, controlling IL-22 and thereby the development of colon cancer.
METHODS SUMMARY
Tumour induction. Co-housed mice were injected intraperitoneally with AOM (azoxymethane) (Sigma) at a dose of 7.5 mg kg 21 body weight. After 5 days, mice were fed 2-2.5% DSS (MP Biomedicals, molecular mass 36,000-50,000 Da) in the drinking water for 5 days, followed by 16 days of regular water. This cycle was repeated twice. Endoscopic procedures. Colonoscopy was performed in a blinded fashion for colitis and tumour monitoring using the Coloview system (Karl Storz). Colitis scoring was based on granularity of mucosal surface, stool consistence, vascular pattern, translucency of the colon and fibrin visible (0-3 points for each). Tumour sizes were graded from 1 to 5. The total tumour score per mouse was calculated as sum of all tumour sizes. In some experiments the colon was wounded using the endoscopy and a biopsy forceps. A re-biopsy was taken 2 days after the wounding close to the initial biopsy. A control biopsy was taken at a distance of about 0.5 cm. Statistical analysis. For comparison of groups, the non-parametric two-sided Mann-Whitney test or analysis of variance (ANOVA) and post-hoc analysis was applied. The significance level a was set to 0.05. 
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